Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is a fact that LWE is the largest retail shareholder in SING.
An interesting and decent SinglePoint PR this morning inmo, a better one would have been announcing that Rip had the pleasure of taking Greg to the train station....
Perhaps a more appropriate question might be 'What the heck is right with this company'?
Inmo, whatever is right with this company is completely overshadowed/smothered by GL's pathologic ego to include his impressive depth of managerial incompetence....
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK® May 11, 2020 DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc."
https://ir.navidea.com/press-releases/detail/344/navidea-biopharmaceuticals-regains-commercialization-and
To buy said 4.7kk shares insiders such Greg would have to come up with basically pocket change in the in the range of $25,380-$26,790. Better yet Greg double up on the buy to 9.4kk shares and make a real impact on the SP. Just do it Greg and make it onto a Christmas card list or two this year, would ya?
I'm definitely in Lwe....
If the pps does indeed touch/go to $0.0 then some to much of the responsibility falls squarely upon the shoulders of the CEO as clearly documented by Greg's hoof in mouth disease or diarrhea of the mouth, take your pick, smh.....
Nice post lwe, thanks for sharing!
Siggy, yes as that I've been medical/cardiology/cardiovascular sales since 1983 and do remember when viagra was in clinicals with cardiologists discussing with some levity its unintended findings before its final approval/labeling.....
The Villages and other retirement communities in Florida have been gettin' busy for some time now due to pharmaceutical aids. A billboard extolling the benefits of CBD oil combined with viagra, cialis, etc...may indeed be an opportunity as that vanity and the search for the fountain of middle age are motivations difficult to deny...
yiannisf: Your appearance on this mb is as timely as it is expected, a harbinger if you will of a pps trajectory in ascension, inmho.
>$.02......
Duly noted.....
Lwe is the largest retail shareholder of Singlepoint, fact, while sigggy is at best a wannabe paid short shill....
Demi, fwiw.... Global warming /cooling is real, Man made global warming is a scam, an attempt at wealth transference, and isn't close to actual /real as parlayed as that every model has been proven wrong in its prediction(s) even after the data was falsified. As for the decrease or increase of temperature(and it does) over any designated time frame, it's called weather. Trump is referring to the latter. Links for your review....
https://www.investors.com/politics/editorials/the-stunning-statistical-fraud-behind-the-global-warming-scare/
https://skepticalscience.com/human-co2-smaller-than-natural-emissions.htm
https://www.forbes.com/sites/alexepstein/2015/01/06/97-of-climate-scientists-agree-is-100-wrong/
https://www.dailymail.co.uk/sciencetech/article-2171973/Tree-ring-study-proves-climate-WARMER-Roman-Medieval-times-modern-industrial-age.html
http://www.independent.org/store/book.asp?id=42&s=ga&gclid=Cj0KCQjwtr_mBRDeARIsALfBZA7jWbBUOjiYc8F1bIq0q-_GkSD6DJundTSEHCFkCuH3TRCPtlU0BkYaArE3EALw_wcB
https://www.climate.gov/teaching/resources/70s-they-said-thered-be-ice-age
https://www.theatlantic.com/science/archive/2019/01/sea-level-rise-may-not-become-catastrophic-until-after-2100/579478/
https://www.thenewamerican.com/tech/environment/item/22289-climate-alarmists-have-been-wrong-about-virtually-everything
https://realclimatescience.com/2017/02/nasa-noaa-climate-data-is-fake-data/
Demi, fwiw.... Man made global warming is a scam, an attempt at wealth transference and isn't close to actual /real as parlayed as that every model has been proven wrong in its prediction(s) even after the data was falsified. As for the decrease or increase of temperature(and it does) over any designated time frame, it's called weather. Links for your review....
https://www.investors.com/politics/editorials/the-stunning-statistical-fraud-behind-the-global-warming-scare/
https://skepticalscience.com/human-co2-smaller-than-natural-emissions.htm
https://www.forbes.com/sites/alexepstein/2015/01/06/97-of-climate-scientists-agree-is-100-wrong/
https://www.dailymail.co.uk/sciencetech/article-2171973/Tree-ring-study-proves-climate-WARMER-Roman-Medieval-times-modern-industrial-age.html
http://www.independent.org/store/book.asp?id=42&s=ga&gclid=Cj0KCQjwtr_mBRDeARIsALfBZA7jWbBUOjiYc8F1bIq0q-_GkSD6DJundTSEHCFkCuH3TRCPtlU0BkYaArE3EALw_wcB
https://www.climate.gov/teaching/resources/70s-they-said-thered-be-ice-age
https://www.theatlantic.com/science/archive/2019/01/sea-level-rise-may-not-become-catastrophic-until-after-2100/579478/
https://www.thenewamerican.com/tech/environment/item/22289-climate-alarmists-have-been-wrong-about-virtually-everything
https://realclimatescience.com/2017/02/nasa-noaa-climate-data-is-fake-data/
So are you then fully liquidating your SING postion as that you posted last week that 300k shares was all that you retained after your 1.8kk sell. If so.... sayonara!
"So glad i sold 3 weeks ago." You sold out and yet you still post quite often; Why? Simply curious as to what motivates someone to waste their time in that fashion.
Thank you for sharing Lwe6638!
Lwe6638, much to look forward to relative to PR's in the next 30+- days, inmo....
NAVB institutional hold increases to 52,621,678 or 34.92% of the total shares outstanding. GS increases their position to 4,201,871, an increase of 30.62% and these numbers only reflect thru 6/30/2015. what say you casper and diddo? a good time to short since all is doom & gloom per recent posts by you both? more crocodile tears forthcoming? just askin`, LOL!
Ownership Summary
Institutional Ownership 34.92%
Total Shares Outstanding (millions) 151
Total Value of Holdings (millions) $88
Active Positions
HOLDERS SHARES
Increased Positions 36 3,342,895
Decreased Positions 27 748,965
Held Positions 28 48,529,818
Total Institutional Shares 91 52,621,678
New and Sold Out Positions
TotalActiveShares
New/SoldShares
0M
-2.5M
2.5M
5M
HOLDERS SHARES
New Positions 8 328,580
Sold Out Positions 10 131,924
Total Shares New Increased Decreased Activity Sold Out
91 Institutional Holders
52,621,678 Total Shares Held
Click on the column header links to resort ascending (?) or descending (?).
Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
PLATINUM MANAGEMENT (NY) LLC 06/30/2015 12,192,327 737,496 6.44 20,361
COMMERZBANK AKTIENGESELLSCHAFT /FI 06/30/2015 6,702,002 0 0.00 11,192
SUSQUEHANNA INTERNATIONAL GROUP, LLP 06/30/2015 6,150,731 66,655 1.10 10,272
VANGUARD GROUP INC 06/30/2015 4,571,668 56,950 1.26 7,635
GOLDMAN SACHS GROUP INC 06/30/2015 4,201,871 985,092 30.62 7,017
BLACKROCK FUND ADVISORS 06/30/2015 3,942,167 (264,755) (6.29) 6,583
STATE STREET CORP 06/30/2015 2,083,684 35,695 1.74 3,480
UBS GROUP AG 06/30/2015 1,917,029 337,651 21.38 3,201
NORTHERN TRUST CORP 06/30/2015 1,500,065 (59,516) (3.82) 2,505
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A. 06/30/2015 1,454,959 (106,677) (6.83) 2,430
GEODE CAPITAL MANAGEMENT, LLC 06/30/2015 746,488 3,541 .48 1,247
BANK OF NEW YORK MELLON CORP 06/30/2015 719,692 44,824 6.64 1,202
BRIDGEWAY CAPITAL MANAGEMENT INC 06/30/2015 649,880 0 0.00 1,085
BLACKROCK INVESTMENT MANAGEMENT, LLC 06/30/2015 561,782 105,325 23.07 938
TIAA CREF INVESTMENT MANAGEMENT LLC 06/30/2015 527,413 (13,133) (2.43) 881
Read more: http://www.nasdaq.com/symbol/navb/institutional-holdings#ixzz3itPbivcc
750k huh casperzelkushondadennis? not even close. SHORT POSITION INCREASES 235,799OR .8%, BASICALLY FLAT!
you`re not doin your part casper....SHORT NAVB NOW, just do it basher!
Short Interest: NYSE MKT Company By Company | NYSE | Nasdaq SHORT INTEREST: Highlights
N Listings | 0-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | O | P | Q | R | S | T | U | V | W | X | Y | Z
Tuesday, August 11, 2015
Symbol 7/31/15 7/15/15 Chg %Chg %Float Days/cvr Avg daily
NAVB 30,199,779 29,963,980 235,799 0.8 20.3 57 525,933
BooDog: this Journal Article's findings may just be used as well to contribute to the understanding/expectations relative to the intricacies of a conjugated Manocept molecule in a therapeutic application. more kinetic/mechanism of action after market/phase 4 studies ongoing I'm a bettin' too.
CarefulTrade: reasoned and nicely done. actual BP developmental partnership(S) inmo is indeed the metric that will determine initial value of the MT pipeline. as a long since 1999 i am somewhat suprised in finding myself actually excited at the prospects considering all the twists and turns especially since 2009. thank-you!
courtesy of moneyonomics on I.V.-OTL & NAVB mb.....
Msg 13842 of 13842 at 6/27/2015 10:42:15 PM by moneyonomics
Msg 8638 of 8638 at 6/27/2015 10:39:58 PM by moneyonomics
Manocept passes BBB: "..combinatorial therapies equipped with precise delivery tools (including to CNS resident macrophages ie passing BBB) can fulfill the scientific dream of the complete eradication of HIV-1 from infected patients." Kumar/Herbein 2014
The macrophage: a therapeutic target in HIV-1 infection
Amit Kumar1 and Georges Herbein12*
* Corresponding author: Georges Herbein georges.herbein@univ-fcomte.fr
Author Affiliations
1 Department of Virology, UPRES EA4266 Pathogens & Inflammation, University of Franche-Comte, SFR FED 4234, F-25030 Besançon, France
2 Department of Virology, Hôpital Saint-Jacques, CHRU Besançon, 2 place Saint-Jacques, F-25030 Besançon cedex, France
Molecular and Cellular Therapies 2014, 2:10 doi:10.1186/2052-8426-2-10
Received: 27 October 2013
Accepted: 27 January 2014
Published: 2 April 2014
© 2014 Kumar and Herbein; licensee BioMed Central Ltd.
http://www.molcelltherapies.com/content/2/1/10
These results collectively revealed that macrophages play a central role in the propagation of HIV-1 infection, in depletion of CD4+ and CD8+ T cells, and in conferring anti-apoptotic characteristics to the HIV infected cells thereby favoring the expansion of the viral reservoir.
Macrophages and cytotoxic T cells (CTLs)
HIV-1 specific cytotoxic T cells (CTLs) play an important role in controlling HIV-1 infection during early stage of infection [88,89]. CTLs act on the information provided by CD4+?T cells or antigen presenting cells [90]. However, in HIV-1 infected patients even effective CTLs response is also hampered. Studies showed that Nef downregulates the expression of HLA class I molecule in infected CD4+ T cells resulting in their escape from HIV-1 specific CTLs [91]. Interestingly, Fujiwara and Takiguchi, in their in vitro study demonstrated that HIV-1 specific CTLs are capable of effectively suppressing R5 virus replication in infected macrophages [92]. Furthermore, their data revealed that HIV-1 infected macrophages induce more proliferation of HIV-1 CTLs as compared to infected CD4+ T cells. Taken together data suggest the involvement of effective response of macrophages during early phase of HIV-1 infection [92]. However, in vivo the role of HIV-1 infected macrophages is largely influenced by their activation states [15]. Notably, macrophages are proposed to be in three kinds of activation states which are designated as M1 (pro-inflammatory in nature), M2 (anti-inflammatory in nature) and deactivated macrophages. Of note, M1 macrophages produce cytokines IL-23, IL-12, IL1-ß, TNF-a and support Th1 response [15,93,94]. On the other hand, in M2 activation state, macrophages secrete IL-10 and support Th2 responses [15,94]. According to proposed model, during early stage of HIV-1 infection, M1 activation is predominant which favors robust HIV-1 transcription and formation of viral reservoirs [15]. As the infection progressed, M1 state is off and M2 activation state is predominant followed by deactivation of macrophages resulting finally in failure in presenting antigen to the CTLs [15]....
...Macrophage targeted carriers
Effective therapeutic agent must be complimented with effective delivery tools for the successful delivery of results. Nanotechnology has made it possible to deliver the therapeutic agents to specific cell types or anatomical location which otherwise are not accessible by conventional delivery methods [149]. It is assumed that anti-HIV drugs delivered via nano-carrier can be selectively accumulate in infected cell types while uninfected cells will have much lower concentration of drugs therefore, will have less side effects [150]. Wan and colleagues have developed nano-carrier based system for drug delivery in macrophages using formyl methionine-leucine-phenylalanine (fMLF) peptide-PEG derivatives [151]. fMLF are employed because fMLF receptors are specifically present on phagocytic cells including macrophages and fMLF binds to the receptors present on macrophages with high affinity [151,152]. Bio-distribution of fMLF-PEG nano-carrier was studied in vivo, revealed the greater accumulation of fMLF-PEG into macrophages of kidneys, spleen and liver as compared to only PEG [152]. Results are encouraging and suggest the feasibility of specifically targeting HIV-1 reservoir in macrophages....
...In addition, brain resident macrophages represent the anatomical sanctuaries where drug penetration is poor and determination of drug efficacy in these sanctuaries is rather a difficult task [180,181]. Furthermore, the presence of efflux pumps and array of metabolic enzymes in blood brain barrier further put the efficacy of drugs in a difficult proposition. CNS resident macrophages play an important role in HAD, a severe morbidity of HIV-1 infection. Treating HIV-1 needs holistic view where besides T lymphocytes cells of monocyte/macrophage lineage must be taken into consideration. Ignoring one or other viral reservoir will not result in any favorable outcome.
Conclusion
Macrophages are among the early targets of HIV-1. They also act as chronic and latent viral reservoirs. Although ART has suppressed viremia in most of infected patients, complete eradication is not possible without clearance of HIV-1 from latent reservoirs. Novel therapeutics options have emerged against these reservoirs. However, delivery of therapeutic molecules in vivo is still a major challenge. In the future, combinatorial therapies equipped with precise delivery tools can fulfill the scientific dream of the complete eradication of HIV-1 from infected patients.
http://www.molcelltherapies.com/content/2/1/10
octamatta: the mb will not let me post the balance of your alias. 1.you may be correct relative to the Russel re-balancing on 6/19/2015. 2. the NAVB pps going green thing as of yesterday may just continue next week going into the MCgrath presentations on 7/1-7/2/2015 in Hollywood, FL. 3. the following below are excerpts from Rick Gonzales, CEO-NAVB relative to the MANOCEPT PLATFORM. maybe some intrinsic value possibly adding to the pps in the not to distant future starting with yesterday/6/26/2015, we`ll see soon enough. GLTALs!
RG:
On the contrary, where Lymphoseek sits on the Manocept for localization purposes, you see that in the KS patient, there's no such localization. So it tells us is that it has Manocept, has a selective ability to target these activated macrophages and the distribution -- its distribution is a significant improvement over existing agents.
Strategies to target the critical disease-causing macrophages is to block endogenous macrophage specifically activating agents. Some early promise, but they suffer from excess toxicity.
Stimulating macrophage activation by administration of macrophage-activating agents, there's toxicity due to lack of specificity and significant off-target effects. Targeting specific compounds produced by overactivated macrophage, for example that VEGF, TNF, MMPs and [IDOs] have a very valuable effect.
So as I mentioned before, we have, in the disease target selection -- we have a core of working group international experts that are helping us to advise on not only macophage behavior but disease target selection as a process to get through the development process. We will continue to evolve this as we choose additional disease targets and we will be able to reinforce our knowledge of what do we need to do to take this Manocept backbone and unlock its full potential.
To that effect, there will be data that will be released very, very soon to the ability that, if you substitute the payload onto the Manocept backbone, what happens? Not only do we have the ability to target effectively and selectively, as I said, but also what happens and what impact can we have in the apoptotic death of these overactive macrophages. So stay tuned for that...
http://finance.yahoo.com/news/edited-transcript-navb-presentation-1-103237336.html
Hey dingdong: while the $ 1.58 end of day thing didn`t work out for ya maybe the Russell re-balancing that (supposedly) took place on 6/19/2015 will. we will know after 7/3/2015 in that in previous years the Russell has re-balanced at times on the last Friday of June or the first Friday of July. best to withhold judgement until July 3rd, end of day before the issuing of edicts relative to the re-balancing thing.
CarefulTrade: please note the increase/volume on the dates of:6/22/2012, 6/28/2013, and 6/27/2014 as they are bracketed between the trading days preceding and following. fwiw, my source is the NASDAQ-historical prices.
date volume
06/25/2012 550,162
06/22/2012 1,116,489
06/21/2012 644,302
date
07/01/2013 480,902
06/28/2013 1,767,440
06/27/2013 763,130
date
06/30/2014 502,352
06/27/2014 2,500,994
06/26/2014 710,563
Careful, the Russell may have re-balanced though i`m not 100% convinced...yet. was their any significant after hours volume to your recollection on Friday(6/19/2015) as that i missed the opportunity to check? if memory serves in years past(2014, 2013, 2012) the AH showed significant volume.
"I made my bet too, Boo..most of it, right before Crede between 2.75 and 2.99. There is no justice with this stock (and nor will there be). But the morons and the company may yet be dealt with someday.
All of this talk about Manocept being 2-3 years out, or even longer, is absolutely sickening. I understand the shorts more and more - another share offering will be need IF Manocept takes even 12 months to really develop. Wonderful!"
sell your supposed shares zelkuscasperhonda, the micro biotech thing ain`t your cup of tea.....
the good news is a pilin` up shorty and bashers.....
Navidea Reports Positive Lymphoseek® Comparative Results in Injection Site Pain Study in Breast Cancer
Published: June 8, 2015 4:30 p.m. ET
- Study Presented at the 2015 Society of Nuclear Medicine and Molecular Imaging Conference -
DUBLIN, Ohio, Jun 08, 2015 (BUSINESS WIRE) -- Navidea Biopharmaceuticals (nyse mkt:NAVB), announced that results from an investigator-initiated, comparative study of Lymphoseek® (technetium Tc 99m tilmanocept) injection versus filtered Tc-99m Sulfur Colloid (fTcSC) measuring injection site pain in patients with breast cancer undergoing lymphoscintigraphy were presented at the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. The results of the randomized, double-blinded trial, led by Anne Wallace, M.D., professor of surgery at University of California, San Diego School of Medicine, highlighted that fTcSC caused statistically significant greater levels of pain after injection compared to Lymphoseek.
In preparation for Sentinel Lymph Node Biopsy in breast cancer and other cancers, lymphatic pathways are mapped using a procedure called lymphoscintigraphy. “Patients often fear this procedure given the evidence of injection pain from some radiotracers,” said Dr. Wallace, who is also director of the Comprehensive Breast Health Center at UC San Diego Moores Cancer Center. “This study of tilmanocept demonstrated, with patient-reported data, a significantly reduced level of post-injection associated pain compared with use of an fTcSC tracer. Along with its other desirable performance characteristics, surgeons now have a reliable tool that can potentially play an important role in improved patient comfort and management.”
“This investigator-initiated study is of particular importance as it continues to reinforce the clinical value of Lymphoseek,” said Michael Tomblyn, M.D., Navidea’s Executive Medical Director. “While previous studies have reported on Lymphoseek efficacy and ongoing safety, these results further illustrate both the clinical utility and clear benefits to both surgical oncologists and patients.”
The poster presentation entitled, ”A Randomized Double-Blinded Comparison of Injection Site Pain of Tc-99m Tilmanocept versus Filtered Tc-99m Sulfur Colloid in Patients Undergoing Lymph Node Mapping for Breast Cancer” showed results of the randomized, double-blind clinical trial comparing post-injection site pain using fTcSC versus Lymphoseek in 52 [(27) fTcSC and (25) Lymphoseek] breast cancer patients undergoing lymphoscintigraphy. Pain was evaluated with a visual analogue scale and short form McGill Pain Questionnaire at 1, 2, 3, 4, 5, 15 and 30 minutes post-injection. Analysis of the data indicates baseline pain scores were similar between groups. At one minute post-injection, patients receiving fTcSC experienced a mean change in pain of 16.8mm (standard deviation (SD) 19.5) compared to 0.2mm (SD 7.3) in the Lymphoseek group (p =0.0002). Overall, patients receiving Lymphoseek experienced statistically significant less change in pain scores compared to patients receiving fTcSC at 1-3 minutes post-injection.
Navidea Biopharmaceuticals, Inc. (NAVB) After Hours Trading
NAVB $1.57* 0.1510.56%
*Delayed - data as of 06/08/2015 16:43 - Find a broker to begin trading NAVB now Exchange: AMEX
Industry: Health Care
Community Rating: Bullish
NAVB After Hours
Jun. 8, 2015 Market Close: $ 1.42 Pre-Market Charts | After Hours Charts
View most recent trades for the selected time period:
After Hours Volume: After Hours High: After Hours Low:
52,622 $ 1.59 $ 1.42
(16:31:29 PM) $ 1.42
(16:30:54 PM)
Trade Detail
Most Active in the After-Hours
After Hours Time (ET) After Hours Price After Hours Share Volume
16:43 $ 1.57 700
16:40 $ 1.56 100
16:40 $ 1.56 900
16:40 $ 1.56 100
16:40 $ 1.55 8,000
16:40 $ 1.55 1,000
16:37 $ 1.53 1,000
16:36 $ 1.52 100
16:36 $ 1.52 900
16:31 $ 1.59 High 1,000
16:31 $ 1.57 100
16:31 $ 1.57 900
16:31 $ 1.57 100
16:31 $ 1.54 200
16:31 $ 1.54 800
16:31 $ 1.52 6,100
16:30 $ 1.42 Low 4,172
16:30 $ 1.52 1,000
16:30 $ 1.52 400
16:30 $ 1.50 50
16:30 $ 1.50 3,900
16:30 $ 1.50 700
16:30 $ 1.50 3,000
16:30 $ 1.50 4,300
16:30 $ 1.50 700
16:30 $ 1.50 800
16:30 $ 1.50 4,000
16:30 $ 1.50 800
16:30 $ 1.50 1,800
16:30 $ 1.49 1,200
16:30 $ 1.49 800
16:30 $ 1.49 3,000
Read more: http://www.nasdaq.com/symbol/navb/after-hours#ixzz3cVSUN7M1
http://www.marketwatch.com/story/navidea-reports-positive-lymphoseek-comparative-results-in-injection-site-pain-study-in-breast-cancer-2015-06-08?siteid=nbsh
the term to use in the context that is provided along the the lines of a child`s imaginary friend is delusional not disillusioned. if ya are gonna throw a zing someone`s way casperhonda then use the correct word so as to avoid the foot in mouth thing, just sayin`. as to you being a NAVB long, now that is as pure an example of a poster being delusional that i can at present post, lol!
an argument that obstinate youngsters MIGHT have empathy for. it`s about contracts and full filling said contractual obligations. grow up caspeboo....
poor attempt at puerile humor about a phone call that is a figment of your imagination casper. as to a pps that may decline to +- a 1.00....MY GTC ORDER IS IN FOR 3000 NAVB SHARES @ a $1.00. hopin` you are a shortin` NAVB and that i`m a buyin some of those shorted shares....
BooDog: it would seem Platinum-Montaur and yourself are on the same wavelength. the clowns on this mb and other mb`s are gonna have a meltdown....
Msg 13746 of 13746 at 5/21/2015 5:14:50 PM by moneyonomics
The following message was updated on 5/21/2015 5:20:49 PM.
EBITDA/Sales covenants in CRG loan. Annually $5 mm ebitda-$11mm sales from LS in 2015 with sales target moving to $45 mm in 2020. PM must also cover any negative ebitda
"... The covenants of the CRG Loan Agreement include a covenant that the Company shall have EBITDA of no less than $5 million in each calendar year during the term or revenues from sales of Lymphoseek? in each calendar year during the term of at least $11 million in 2015, with the target minimum revenue increasing in each year thereafter until reaching of $45 million in 2020, which will also be the target minimum revenue in each calendar year thereafter during the term. If the Company fails to meet the applicable EBITDA or minimum revenue target in any calendar year, the Loan Agreement provides the Company a cure right if it raises 2.5 times the EBITDA or revenue shortfall in equity or subordinated debt and deposits such funds in a separate blocked account. Finally, the events of default under the CRG Loan Agreement include a failure of Platinum-Montaur Life Sciences, LLC ("Platinum") to perform its funding obligations under the Platinum Loan Agreement (as defined below) at any time as to which the Company had negative EBITDA for the most recent fiscal quarter, as a result either of Platinum's repudiation of its obligations under the Platinum Loan Agreement, or the occurrence of an insolvency event with respect to Platinum...."
" Platinum either has a lot of confidence in NAVB growth potential or they expect the company to be sold before the covenants become onerous." Zanispetros-I.V.(NAVB mb)
short position decreases 1.5%/488,813shares to 28.541kkshares(4/30/2015), down from a high of 31.7kkshares(12/15/2014), a total reduction of 3.23kkshares/10.2%. the next short dissemination report is on Wednesday, 5/27/2015.
"the short interest is going to start building further as the shorts start to finish this garbage stock and company off once and for all."
shorts are gonna finish off NAVB once and for all heh? hmmm....we`ll see
and yet you still post/bash NAVB peter instead of what any RATIONAL adult would do, that is exit/move on. ohh check that...you supposedly sold then bought back in?/!*# wth is that about unless 1.ya never had any NAVB to begin with and were retail shorting NAVB from the beginning. 2.ya actually had a position then sold and GOT BACK IN which indicates a clear pathology as demonstrated via all the posted schizophrenia. 3. a post turtle? not enough medicine... too much?
from the Journal of Cytology & Molecular Biology:
Review Article
"Exploitation of the Macrophage Mannose Receptor (CD206) in Infectious Disease Diagnostics and Therapeutics"
http://fulltextarticles.avensonline.org/jcmb-2325-4653-01-0003.html
much appreciation and kudos to Neers87(IV/NAVB mb) for sharing....
sts66: NAVB has been negotiating with NORGINE for well over a year. the approval by the EMA simply was the catalyst to ink the agreement inmo. the time frame to conclude said agreement since EMA approval looks to be appropriate from my perspective given the time frame from which initial negotiations began.
Navidea and Norgine Enter European Commercial Partnership for Lymphoseek®; Navidea to Receive $2 Million Upfront Payment
http://www.marketwatch.com/story/navidea-and-norgine-enter-european-commercial-partnership-for-lymphoseek-navidea-to-receive-2-million-upfront-payment-2015-03-05?siteid=nbsh
- Strategic partnership provides market development, sales and marketing infrastructure for Lymphoseek expansion into European marketplace –
DUBLIN, Ohio, Mar 05, 2015 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc. (nyse mkt:NAVB) and SpePharm AG (an affiliate of Norgine BV), a European specialist pharmaceutical company with an extensive pan-European presence, today entered into an exclusive sublicense agreement for the commercialization and distribution of Lymphoseek® 250 microgram kit for radiopharmaceutical preparation (tilmanocept) in the European Union. Under the terms of the agreement, Navidea will receive an upfront payment of $2 million and is eligible to receive additional milestone payments up to $5 million, as well as royalties on European net sales.
Lymphoseek is a receptor-targeted, radiopharmaceutical imaging agent approved by the U.S. Food and Drug Administration in 2013 and by the EU in November 2014. Lymphoseek is approved in Europe for imaging and intraoperative detection of sentinel lymph nodes in patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity. In these procedures, key lymph nodes adjacent to a primary tumor, that may contain tumor metastases, are identified and biopsied to determine if cancer has spread to these lymph nodes.
“Launching Lymphoseek into new global markets is integral to Navidea’s corporate growth strategy. We believe that Norgine’s commercial, medical and development expertise, combined with its well-established infrastructure and strong presence in the European marketplace, make it an ideal commercialization partner to gain country-by-country reimbursement and drive Lymphoseek adoption,” said Rick Gonzalez, President and Chief Executive Officer of Navidea. “We anticipate a successful and mutually-beneficial partnership with Norgine based on synergistic core competencies, our shared vision for value creation and our strong commitment to providing highly-differentiated products that improve the diagnosis and treatment of disease for patients with unmet medical needs.”
“This agreement with Navidea underscores Norgine’s vision to be the partner of choice and facilitates the growth and expansion of our specialist product portfolio to help improve the treatment of patients throughout Europe,” said Peter Stein, Chief Executive Officer of Norgine. “We look forward to fully engaging our sales force to support commercial launch activities in a marketplace requiring a new alternative.”
“Securing a partner with the commitment to market access development was especially important to us since, unlike the United States where institutions typically rely on unit dose distribution of radiopharmaceutical products by specialized radio-pharmacy distributors, institutions in Europe purchase non-radiolabeled material and compound the finished product on-site,” added Mr. Gonzalez “As a specialist pharmaceutical company, Norgine is optimally positioned to interface directly with a targeted surgical oncologist customer base with a dedicated sales force. We expect Norgine to begin market access work immediately in the major markets in Europe with the goal of supporting commercial launch sometime in early 2016.”
Under terms of the exclusive license agreement, Navidea will supply Lymphoseek product to Norgine; however, Navidea will transfer responsibility for regulatory maintenance of the Lymphoseek Marketing Authorization to Norgine. Norgine will also be responsible for pricing, reimbursement, sales, marketing, medical affairs, and regulatory. In connection with entering into the agreement, Navidea will be entitled to an upfront payment of $2 million, milestones totaling up to an additional $5 million, as well as royalties on European net sales. The initial territory covered by the agreement includes all 28 member states of the European Economic Community with the option to expand into additional geographical areas. Additional terms of the agreement were not disclosed.
Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Appoints Leading Experts to Therapeutics-Focused Scientific Advisory Board
DUBLIN, Ohio--(BUSINESS WIRE)--Feb. 27, 2015-- Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced the appointment of leading experts to a newly formed scientific advisory board (SAB) to serve as a strategic resource to Macrophage Therapeutics as it looks to develop therapeutic applications for Navidea’s innovative Manocept™ platform. The inaugural SAB consortium is comprised of world-renowned scientists and clinicians in the areas of oncology, immunology, autoimmune diseases and macrophage biology. The SAB will serve as an ongoing resource to provide management with counsel and guidance pertaining to the research, development, and clinical application of Manocept technology.
“While Macrophage Therapeutics is a newly created entity, the proprietary Manocept technology on which it is based, is well advanced. The demonstrated activity in immunotherapy of the platform suggests promise in a broad range of therapeutic areas. In order to ensure the most rapid development of products that address markets with large unmet medical needs, we are creating an advisory board committed to being actively engaged with management to evaluate and prioritize opportunities. The SAB is initially comprised of scientists who have had direct experience with our technology as well as prominent experts in the area of immunology. This board will be augmented with experts with specific therapeutic area expertise as potential applications grow,” said Michael Goldberg, M.D., Navidea Director and Macrophage Therapeutics Chief Executive Officer. “In addition, the previously announced initial funding for Macrophage Therapeutics is progressing towards closing next week.”
"We believe the Manocept platform may provide important new opportunities across a range of clinical indications where significant unmet medical need exists," stated Frederick O. Cope, Ph.D., FACN, Navidea Senior Vice President and Chief Scientific Officer. "We are very pleased to bring together these key thought leaders to establish the Macrophage Therapeutics Scientific Advisory Board. Their deep insight into macrophage science and macrophage-mediated diseases will be instrumental in prioritizing and advancing our therapeutic research programs."
The inaugural members of Macrophage Therapeutics’ Scientific Advisory Board include:
Siamon Gordon, M.B., Ch.B., Ph.D.
Glaxo Wellcome Professor of Cellular Pathology (Emeritus), University of Oxford
Mark I. Greene, M.D., Ph.D., F.R.C.P.
John Eckman Professor of Medical Sciences, Vice Chair of Pathology, Division of Immunology and Experimental Pathology, University of Pennsylvania
Wael Jarjour, M.D.
Associate Professor, Director, Division of Rheumatology & Immunology, The Ohio State University
Michael S. McGrath, M.D., Ph.D.
Professor, Departments of Laboratory Medicine, Pathology, and Medicine, University of California San Francisco
Thomas J. Rosol, D.V.M., Ph.D.
Professor, Veterinary Sciences, The Ohio State University; Senior Advisor, Life Sciences, University Office of Technology Commercialization and Knowledge Transfer, The Ohio State University; Special Assistant to the Vice President for Research, The Ohio State University
Eric K. Rowinsky, M.D.
Head of Research and Development and Chief Medical Officer,Stemline Therapeutics, Inc. and Director of Navidea Biopharmaceuticals
Larry S. Schlesinger, M.D.
Chair, Department of Microbial Infection and Immunity, Director, Center for Microbial Interface Biology, The Ohio State University
David Sidransky, M.D.
Professor of Otolaryngology – Head and Neck Surgery, Professor of Oncology, Professor of Pathology, Professor of Cellular & Molecular Medicine, Professor of Urology, and Director, Head and Neck Cancer Research, The Johns Hopkins University
Kenneth C. Williams, Ph.D.
Professor of Biology, Boston College
About Macrophage Therapeutics
Macrophage Therapeutics, a newly created subsidiary of Navidea Biopharmaceuticals, Inc., is developing innovative macrophage-targeted therapies for oncology, inflammatory, autoimmune and cardiovascular applications based on Navidea’s proprietary CD206 targeting technology platform, Manocept™. Depending on the active agent(s) attached to the Manocept backbone as well as other core molecule permutations, it is possible to approach immunotherapy in a completely novel manner. This approach has the potential to provide for management and modification of diseases that include the immediate involvement of macrophages, the biological products of macrophages, or the effective impact of macrophages or their progenitor and/or daughter elements. Thus, the Manocept platform is designed to specifically address a key element, macrophage interactions, in the natural progression of clinically significant diseases that impact the lives of patients around the globe.
http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-newsArticle&ID=2021028
http://lifetechcapital.com/ltc/wp-content/uploads/2015/02/Morning-Note-02-27-15-NAVB.pdf